The Indian pharmaceutical industry is being urged to treat proposed US tariffs on imported generic medicines as a critical catalyst for structural change.
Industry experts argue that the threat of steep levies necessitates an immediate reduction in dependence on the US market, which remains the sector's largest export destination.
The potential imposition of levies reaching 200% on imported off-patent drugs has introduced significant uncertainty into the sector's growth outlook.
The consensus among analysts is that companies must accelerate innovation and diversify their global footprint to mitigate the risk of trade barriers.
Market sentiment has already begun to reflect these concerns.
Pharmaceutical equities faced renewed pressure as the prospect of tariffs gained traction in market commentary.
The potential imposition of levies reaching 200% on imported off-patent drugs has introduced significant uncertainty into the sector's growth outlook.